
[ad_1]

What you need to know:
– Eko Health, a provider of AI-powered heart and lung disease detection, today announced FDA clearance for its low EF detection AI.
– AI built in partnership with Mayo Clinic allows U.S. healthcare providers to use a standard Eko stethoscope during routine physical exams to detect low ejection fraction (LVEF), a key indicator of heart failure. can be detected in just 15 seconds.
The importance of early detection
Advances in early detection represent major medical innovations for cardiovascular disease. In the United States alone, more than 6 million people suffer from heart failure, and half of them experience HFrEF, a condition in which the heart is unable to pump blood efficiently. Traditionally, heart failure diagnosis often relies on echocardiography, but cost, specialized training requirements, and time constraints prevent this tool from being available in many primary care settings. As a result, many heart failure cases are not diagnosed until patients experience severe symptoms, leading to worse outcomes and increased healthcare costs.
Eko’s AI solutions integrate seamlessly into your existing workflows
Eko’s Low EF AI disrupts this paradigm by enabling quick and accessible LVEF detection during routine stethoscope examinations. This integration into existing workflows allows for early intervention and potentially life-saving treatment. Low EF AI seamlessly integrates with Eko’s existing SENSORA Cardiac Early Detection Platform. The platform already features FDA-cleared algorithms for detecting atrial fibrillation (AFib) and structural heart murmurs. If AI detects low EF during primary care testing, patients are immediately referred to cardiology for a definitive diagnosis and treatment plan.
Rigorous clinical verification supports accuracy
Eko’s Low EF AI has been meticulously developed and tested. Below are some key highlights.
Solid training: It is trained on a massive dataset of over 100,000 paired ECGs and echocardiograms from unique patients.
Multi-center clinical research: It was clinically validated in a comprehensive study of over 3,456 patients and demonstrated strong ability to differentiate between normal and low EF.
Independent verification: An independent study by Imperial College London published in Lancet Digital Health further confirmed the accuracy of the AI with an excellent AUROC of 0.85 in detecting LVEF below 40%.
Real world effects: The successful implementation of Eko in over 100 clinics across London and Wales following research from Imperial College London confirms its effectiveness in real-world settings.
Pregnant women’s health: A Mayo Clinic-led study of nearly 1,200 pregnant women in Nigeria demonstrated the ability of AI to identify twice as many cases of cardiomyopathy compared to standard care, potentially improving maternal health outcomes. It was emphasized.
“As the most recognizable symbol of healthcare, the stethoscope touches an estimated one billion lives around the world each year,” said Connor Landgraf, co-founder and CEO of Eko Health. “With Eko’s Low EF AI, we have turned a medical icon into an AI-powered early heart failure detection tool, saving millions of lives in a fraction of the time and cost of echocardiography. We are honored to collaborate with Mayo Clinic on this groundbreaking initiative. ”
[ad_2]
Source link